Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–112 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: omalizumab (Xolair) Clear all
Completed Phase 4 Interventional Results available

Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

NCT00555971
View directory record Official record
Conditions
Aspirin Sensitivity
Interventions
Omalizumab, placebo
Drug
Lead sponsor
David Lang
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction

NCT02266355
View directory record Official record
Conditions
Colon Cancer
Interventions
Omalizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 11, 2026, 2:59 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Anti-IgE in Non-Allergic Asthma

NCT00162773
View directory record Official record
Conditions
Asthma
Interventions
omalizumab, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

NCT03679676
View directory record Official record
Conditions
Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions
Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 11, 2026, 2:59 AM EDT
Not listed No phase listed Observational

Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study

NCT04724278
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Omalizumab for Lupus

NCT01716312
View directory record Official record
Conditions
Systemic Lupus Erthematosus, Sjogren's Syndrome
Interventions
Omalizumab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria

NCT01701583
View directory record Official record
Conditions
Chronic Urticaria
Interventions
Omalizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

NCT01922037
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
145
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 11, 2026, 2:59 AM EDT
Not listed Phase 4 Interventional

Effect of Xolair on Airway Hyperresponsiveness

NCT00208234
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab, Placebo for Omalizumab
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2011 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

NCT01264939
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Omalizumab to Treat Hyper-IgE (Job's) Syndrome

NCT00260702
View directory record Official record
Conditions
Hyper-IgE Syndrome, Job's Syndrome
Interventions
Omalizumab (Xolair)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 76 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

NCT00367016
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Atopic Dermatitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 11, 2026, 2:59 AM EDT
Completed No phase listed Observational

ICATA Asthma Mechanistic Study

NCT00377390
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 20 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 11, 2026, 2:59 AM EDT
Withdrawn Phase 1 Interventional

Xolair Interventional Study in ASD Patients With Comorbid Atopy

NCT04535817
View directory record Official record
Conditions
Autism Spectrum Disorder, Atopy
Interventions
Omalizumab Injection [Xolair]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

NCT01510626
View directory record Official record
Conditions
Immune System Diseases
Interventions
Food proteins, Omalizumab
Dietary Supplement · Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 11, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab

NCT00123630
View directory record Official record
Conditions
Esophagitis
Interventions
omalizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 11, 2026, 2:59 AM EDT